GlucoTrack, Inc.(GCTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GCTK GlucoTrack, Inc.

Not Yet Opened 05-13 16:00:00 EDT

0.5409

-0.0193

-3.45%

盘后0.5036

-0.0373-6.90%

19:27 EDT

High0.6074	Low0.5200	Vol77.40K
Open0.6074	D1 Closing0.5602	Amplitude15.60%
Mkt Cap14.47M	Tradable Cap8.38M	Total Shares26.76M
T/O43.20K	T/O Rate0.50%	Tradable Shares15.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GCTK","market":"US","secType":"STK","nameCN":"GlucoTrack, Inc.","latestPrice":0.5409,"timestamp":1715630400000,"preClose":0.5602,"halted":0,"volume":77396,"hourTrading":{"tag":"盘后","latestPrice":0.5036,"preClose":0.5409,"latestTime":"19:27 EDT","volume":684,"amount":351.4648,"timestamp":1715642863179},"delay":0,"floatShares":15499263,"shares":26756369,"eps":-0.383039,"marketStatus":"Not Yet Opened","change":-0.0193,"latestTime":"05-13 16:00:00 EDT","open":0.6074,"high":0.6074,"low":0.52,"amount":43196.774073199995,"amplitude":0.156016,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.383039,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1715673600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.5602,"postHourTrading":{"tag":"盘后","latestPrice":0.5036,"preClose":0.5409,"latestTime":"19:27 EDT","volume":684,"amount":351.4648,"timestamp":1715642863179},"volumeRatio":0.2882758589209045},"requestUrl":"/m/hq/s/GCTK/","defaultTab":"news","newsList":[{"id":"2432605561","title":"GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION","url":"https://stock-news.laohu8.com/highlight/detail?id=2432605561","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432605561?lang=en_us&edition=fundamental","pubTime":"2024-05-02 13:00","pubTimestamp":1714626000,"startTime":"0","endTime":"0","summary":"Continuous blood glucose monitor’s preclinical data and sensor longevity modeling to be presented at major diabetes conference Rutherford, NJ, May  02, 2024  (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasd","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874254/0/en/GLUCOTRACK-ANNOUNCES-ABSTRACTS-ACCEPTED-FOR-POSTER-PRESENTATION-AT-84TH-SCIENTIFIC-SESSIONS-OF-THE-AMERICAN-DIABETES-ASSOCIATION.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430239394","title":"Director and 10% Owner Drew Sycoff Acquires 182,540 Shares of GlucoTrack Inc (GCTK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2430239394","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2430239394?lang=en_us&edition=fundamental","pubTime":"2024-04-25 14:18","pubTimestamp":1714025929,"startTime":"0","endTime":"0","summary":"In a recent transaction filed with the SEC, Drew Sycoff, serving as a Director and 10% Owner, has purchased 182,540 shares of GlucoTrack Inc  on April 22, 2024. The transaction is documented in an SEC Filing.GuruFocus has detected 2 Warning Sign with GCTK.GlucoTrack Inc is a company that specializes in the development and commercialization of non-invasive glucose monitoring devices for people with diabetes and pre-diabetics. The company's technology is designed to help users manage their blood sugar levels without the need for finger pricks.Over the past year, the insider has engaged in significant stock acquisition activities, purchasing a total of 182,540 shares. There have been no recorded sales by the insider during this period. The recent buy by Drew Sycoff represents a notable increase in the insider's stake in the company.On the date of the insider's latest transaction, shares of GlucoTrack Inc were trading at $1.26, resulting in a market capitalization of $12.816 million.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dEy2ES7NrD2Tx9QmD2Qh7Q--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/ac716110e85c3b76e1aae5d5163d63c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dEy2ES7NrD2Tx9QmD2Qh7Q--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/ac716110e85c3b76e1aae5d5163d63c1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/director-10-owner-drew-sycoff-061849815.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429737454","title":"Nasdaq Rises 0.5%; Tesla Shares Jump After Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2429737454","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2429737454?lang=en_us&edition=fundamental","pubTime":"2024-04-24 22:30","pubTimestamp":1713969027,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38406512/nasdaq-rises-0-5-tesla-shares-jump-after-q1-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2429977346","title":"GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT","url":"https://stock-news.laohu8.com/highlight/detail?id=2429977346","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2429977346?lang=en_us&edition=fundamental","pubTime":"2024-04-22 18:10","pubTimestamp":1713780600,"startTime":"0","endTime":"0","summary":"Rutherford, NJ, April  22, 2024  (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/22/2867146/0/en/GLUCOTRACK-ANNOUNCES-CLOSING-OF-PRIVATE-PLACEMENT.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427242538","title":"Glucotrack announces expansion into epidural glucose monitoring solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2427242538","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2427242538?lang=en_us&edition=fundamental","pubTime":"2024-04-16 21:02","pubTimestamp":1713272560,"startTime":"0","endTime":"0","summary":"Glucotrack  Tuesday said that it was expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy, the company said.  Glucotrack’s sensor has the potential to be integrated with existing SCS devices to measure epidural glucose in patients with PDN who are undergoing SCS treatment. Glucotrack said it has successfully completed preclinical animal testing in an acute setting, and has initiated a long-term animal study to assess sustained epidural glucose monitoring performance. This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring system. Source: Press Release    More on GlucoTrack, Inc.  Financial information for GlucoTrack, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4090020-glucotrack-announces-expansion-into-epidural-glucose-monitoring-solutions","is_publish_highlight":false,"gpt_icon":0},{"id":"2427829946","title":"GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING","url":"https://stock-news.laohu8.com/highlight/detail?id=2427829946","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2427829946?lang=en_us&edition=fundamental","pubTime":"2024-04-16 12:30","pubTimestamp":1713241800,"startTime":"0","endTime":"0","summary":"Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy Rutherford, NJ, April  16, 2024  (GLOBE NEWSW","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/16/2863596/0/en/GLUCOTRACK-ANNOUNCES-EXPANSION-OF-ITS-CONTINUOUS-GLUCOSE-MONITORING-TECHNOLOGY-TO-EPIDURAL-GLUCOSE-MONITORING.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424097239","title":"Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2424097239","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424097239?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"MIAMI, April 02, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-69-110000672.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424148860","title":"GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR","url":"https://stock-news.laohu8.com/highlight/detail?id=2424148860","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424148860?lang=en_us&edition=fundamental","pubTime":"2024-04-02 12:30","pubTimestamp":1712032200,"startTime":"0","endTime":"0","summary":"Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced Implantable Continuous Blood Glucose Monitor technology could tran","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/02/2855948/0/en/GLUCOTRACK-ANNOUNCES-INCREASED-SENSOR-LONGEVITY-FOR-ITS-IMPLANTABLE-CONTINUOUS-BLOOD-GLUCOSE-MONITOR.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418532943","title":"GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY","url":"https://stock-news.laohu8.com/highlight/detail?id=2418532943","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2418532943?lang=en_us&edition=fundamental","pubTime":"2024-03-12 13:30","pubTimestamp":1710221400,"startTime":"0","endTime":"0","summary":"Rutherford, NJ, March  12, 2024  (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/12/2844638/0/en/GLUCOTRACK-EXPANDS-LEADERSHIP-TEAM-WITH-NEW-VICE-PRESIDENT-OF-QUALITY.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2414726678","title":"GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR","url":"https://stock-news.laohu8.com/highlight/detail?id=2414726678","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2414726678?lang=en_us&edition=fundamental","pubTime":"2024-02-27 13:30","pubTimestamp":1709011800,"startTime":"0","endTime":"0","summary":"Rutherford, NJ & Brooklyn Park, MN, Feb.  27, 2024  (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel tec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/02/27/2836038/0/en/GLUCOTRACK-SELECTS-CIRTEC-MEDICAL-AS-MANUFACTURER-FOR-ITS-IMPLANTABLE-CONTINUOUS-BLOOD-GLUCOSE-MONITOR.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2412151326","title":"GlucoTrack Executes Strategic Equity and Warrant Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2412151326","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2412151326?lang=en_us&edition=fundamental","pubTime":"2024-02-17 05:29","pubTimestamp":1708118980,"startTime":"0","endTime":"0","summary":"GlucoTrack (GCTK) has released an update. GlucoTrack, Inc. has successfully completed a strategic transaction with certain shareholders, exchanging...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glucotrack-executes-strategic-equity-and-warrant-transaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glucotrack-executes-strategic-equity-and-warrant-transaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2411368029","title":"Glucotrack names Luis Malavé board chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2411368029","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2411368029?lang=en_us&edition=fundamental","pubTime":"2024-02-13 22:46","pubTimestamp":1707835597,"startTime":"0","endTime":"0","summary":"Glucotrack  said Tuesday that Luis Malavé has been elected as chairman of its board of directors, effective immediately.Malavé currently serves as president of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump.More on GlucoTrack  GlucoTrack stock jumps 13% on preclinical update for glucose monitor Nasdaq grants additional 180 days to Glucotrack to regain compliance Financial information for GlucoTrack, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4066074-glucotrack-names-luis-malav-board-chair","is_publish_highlight":false,"gpt_icon":0},{"id":"2411350859","title":"GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS","url":"https://stock-news.laohu8.com/highlight/detail?id=2411350859","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2411350859?lang=en_us&edition=fundamental","pubTime":"2024-02-13 14:30","pubTimestamp":1707805800,"startTime":"0","endTime":"0","summary":"Rutherford, NJ, Feb.  13, 2024  (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/02/13/2828367/0/en/GLUCOTRACK-ANNOUNCES-THE-APPOINTMENT-OF-LUIS-MALAV%C3%89-TO-CHAIR-OF-THE-BOARD-OF-DIRECTORS.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2409447412","title":"Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2409447412","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2409447412?lang=en_us&edition=fundamental","pubTime":"2024-02-06 20:00","pubTimestamp":1707220800,"startTime":"0","endTime":"0","summary":"MIAMI, Feb. 06, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emerging Growth Conference on February 7 & 8, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-67-120000525.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2402170224","title":"Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream","url":"https://stock-news.laohu8.com/highlight/detail?id=2402170224","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2402170224?lang=en_us&edition=fundamental","pubTime":"2024-01-10 20:00","pubTimestamp":1704888000,"startTime":"0","endTime":"0","summary":"MIAMI, Jan. 10, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 66th Emerging Growth Conference on January 10 & 11, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. Rescheduled to February 8, 2024Clearday, Inc.  Keynote speaker:James Walesa, CEO / Chairman & Dan Policy, Business Development Manager","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-66-120000965.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2400289864","title":"GlucoTrack stock jumps 13% on preclinical update for glucose monitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2400289864","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2400289864?lang=en_us&edition=fundamental","pubTime":"2024-01-03 03:15","pubTimestamp":1704222904,"startTime":"0","endTime":"0","summary":"Shares of GlucoTrack  jumped 13% in afternoon trading Tuesday after the medical device maker said it had successfully completed an initial preclinical study for its implantable continuous glucose monitor. GlucoTrack said the study, which was not meant to be an accuracy study, showed the sensor demonstrated a mean absolute relative difference of 8.1% at Day 30 and 4.5% at Day 60. No significant adverse events were reported. The company also announced it had initiated long-term preclinical testing of the product. It plans to start first-in-human studies later this year.  More on GlucoTrack, Inc.  Nasdaq grants additional 180 days to Glucotrack to regain compliance Financial information for GlucoTrack, Inc.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/485117377/image_485117377.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/485117377/image_485117377.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4051696-glucotrack-stock-jumps-13-on-preclinical-update-for-glucose-monitor","is_publish_highlight":false,"gpt_icon":0},{"id":"2400622068","title":"GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR","url":"https://stock-news.laohu8.com/highlight/detail?id=2400622068","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2400622068?lang=en_us&edition=fundamental","pubTime":"2024-01-02 17:33","pubTimestamp":1704187980,"startTime":"0","endTime":"0","summary":"Rutherford, NJ, Jan.  02, 2024  (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/01/02/2802856/0/en/GLUCOTRACK-ANNOUNCES-EARLY-ACCURACY-DATA-FOR-ITS-IMPLANTABLE-CONTINUOUS-GLUCOSE-MONITOR.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2388313462","title":"Nasdaq grants additional 180 days to Glucotrack to regain compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2388313462","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2388313462?lang=en_us&edition=fundamental","pubTime":"2023-12-01 19:28","pubTimestamp":1701430099,"startTime":"0","endTime":"0","summary":"Glucotrack  has received a notification letter from Nasdaq Stock Market LLC that the Company has been granted an additional 180-day compliance period, or until May 20, 2024, to regain compliance with Nasdaq’s minimum bid price rule. The company received letter from Nasdaq on May 26, 2023 stating that the company is non-compliance to its minimum bid price requirements as the company is trading below $1.00 for the previous 30 consecutive business days.  The company received another letter in November stating that the Nasdaq has granted additional 180 calendar day period to regain compliance GCTK +7% premarket to $0.2515 Source: Press Release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4042133-nasdaq-grants-additional-180-days-to-glucotrack-to-regain-compliance","is_publish_highlight":false,"gpt_icon":0},{"id":"2388479169","title":"GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT","url":"https://stock-news.laohu8.com/highlight/detail?id=2388479169","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2388479169?lang=en_us&edition=fundamental","pubTime":"2023-12-01 06:39","pubTimestamp":1701383940,"startTime":"0","endTime":"0","summary":"Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22477338","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.integrity-app.com","stockEarnings":[{"period":"1week","weight":-0.2923},{"period":"1month","weight":0.2876},{"period":"3month","weight":1.6385},{"period":"6month","weight":2.2312},{"period":"1year","weight":0.3523},{"period":"ytd","weight":1.0685}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0543},{"period":"6month","weight":0.1584},{"period":"1year","weight":0.2656},{"period":"ytd","weight":0.0959}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.155577},{"month":2,"riseRate":0.5,"avgChangeRate":0.064425},{"month":3,"riseRate":0.5,"avgChangeRate":-0.18882},{"month":4,"riseRate":0.666667,"avgChangeRate":0.152109},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.01988},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.016113},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008215},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.139543},{"month":9,"riseRate":0.666667,"avgChangeRate":0.122393},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.163985},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.031015},{"month":12,"riseRate":0.5,"avgChangeRate":0.322427}],"exchange":"NASDAQ","name":"GlucoTrack, Inc.","nameEN":"GlucoTrack, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GlucoTrack, Inc.(GCTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GlucoTrack, Inc.(GCTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GlucoTrack, Inc.,GCTK,GlucoTrack, Inc.股票,GlucoTrack, Inc.股票老虎,GlucoTrack, Inc.股票老虎国际,GlucoTrack, Inc.行情,GlucoTrack, Inc.股票行情,GlucoTrack, Inc.股价,GlucoTrack, Inc.股市,GlucoTrack, Inc.股票价格,GlucoTrack, Inc.股票交易,GlucoTrack, Inc.股票购买,GlucoTrack, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GlucoTrack, Inc.(GCTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GlucoTrack, Inc.(GCTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction